RxSight annual stock-based compensation
2020
2021
2022
2023
2024
2025
RxSight Stock-Based Compensation Growth & History (RXST)
RxSight's stock-based compensation was $31.6M for fiscal 2025.
View full RxSight company overviewRxSight annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $31.6M | $7.0M | +28.32% |
| 2024 | 2024-12-31 | $24.6M | $8.9M | +56.45% |
| 2023 | 2023-12-31 | $15.7M | $4.3M | +38.16% |
| 2022 | 2022-12-31 | $11.4M | $3.8M | +50.46% |
| 2021 | 2021-12-31 | $7.6M | $3.4M | +81.00% |
| 2020 | 2020-12-31 | $4.2M | — | — |
RxSight quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.5M | −$1.1M | −12.66% |
| Q1 2026 | 2026-03-31 | $7.9M | $805,000 | +11.27% |
| Q4 2025 | 2025-12-31 | $7.8M | $535,000 | +7.35% |
| Q3 2025 | 2025-09-30 | $8.1M | $1.6M | +23.75% |
| Q2 2025 | 2025-06-30 | $8.5M | $2.4M | +40.00% |
| Q1 2025 | 2025-03-31 | $7.1M | $2.4M | +52.04% |
| Q4 2024 | 2024-12-31 | $7.3M | $2.9M | +64.56% |
| Q3 2024 | 2024-09-30 | $6.6M | $2.5M | +60.94% |
| Q2 2024 | 2024-06-30 | $6.1M | $2.1M | +54.36% |
| Q1 2024 | 2024-03-31 | $4.7M | $1.4M | +42.52% |
| Q4 2023 | 2023-12-31 | $4.4M | $1.5M | +49.39% |
| Q3 2023 | 2023-09-30 | $4.1M | $1.2M | +41.26% |
| Q2 2023 | 2023-06-30 | $4.0M | $1.1M | +36.19% |
| Q1 2023 | 2023-03-31 | $3.3M | $646,000 | +24.39% |
| Q4 2022 | 2022-12-31 | $3.0M | $45,000 | +1.54% |
| Q3 2022 | 2022-09-30 | $2.9M | $869,000 | +43.17% |
| Q2 2022 | 2022-06-30 | $2.9M | $1.5M | +106.54% |
| Q1 2022 | 2022-03-31 | $2.6M | $1.4M | +113.80% |
| Q4 2021 | 2021-12-31 | $2.9M | — | — |
| Q3 2021 | 2021-09-30 | $2.0M | $771,000 | +62.08% |
| Q2 2021 | 2021-06-30 | $1.4M | — | — |
| Q1 2021 | 2021-03-31 | $1.2M | — | — |
| Q3 2020 | 2020-09-30 | $1.2M | — | — |
RxSight stock-based compensation trends
Over the last five fiscal years, RxSight's stock-based compensation increased from $4.2M to $31.6M, a change of $27.4M. The latest reported quarter, Q2 2026, shows $7.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RxSight source filings ↗